Perramon-Malavez Aida, Buonsenso Danilo, Morello Rosa, Coma Ermengol, Foster Steve, Leonard Paul, Marlow Robin, Martínez-Marcos Montserrat, Mendioroz Jacobo, Vila Jorgina, Creus-Costa Anna, Prats Clara, Roland Damian, Williams Thomas C, Soriano-Arandes Antoni
Computational Biology and Complex Systems (BIOCOM-SC) Group, Department of Physics, Universitat Politècnica de Catalunya (UPC), Catalonia, Spain.
Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Lancet Reg Health Eur. 2025 Jun 3;55:101334. doi: 10.1016/j.lanepe.2025.101334. eCollection 2025 Aug.
Nirsevimab, a novel monoclonal antibody with a long half-life, has received European Union approval to prevent lower respiratory tract infections (LRTIs) caused by respiratory syncytial virus (RSV) during the first season of exposure. It was implemented in Catalonia (Spain) in the 2023-2024 season. Our main objective was to analyse the impact of the nirsevimab on LRTIs presenting to the Emergency Department (ED) in Catalonia (Spain) by comparing presentations to those at five sites in the United Kingdom (UK) and Rome (Italy).
In this multi-national retrospective analysis of emergency department attendances and admissions, we retrospectively collected information for all diagnoses, respiratory diagnoses excluding bronchiolitis, and bronchiolitis, for different age groups from 68 hospitals in Catalonia (Spain), one hospital in Rome (Italy), and four hospitals in the UK (Bristol, Leicester, Glasgow, and Edinburgh), from May 1st, 2018, to April 30th 2024. Applying a generalised linear model (GLM) in Poisson regression, we obtained the risk ratio (RR) and 95% confidence intervals (CI) of bronchiolitis in 2023-2024 season compared to the mean of all previous seasons. We analysed data in annual bins, from May 1st to April 30th, excluding 2020-21 as a COVID year, for a total of 5 years of data.
Data was available for 1,574,392 ED attendances (96,028 for bronchiolitis) and 255,689 hospital admissions (27,691 for bronchiolitis). In the 2023-2024 season, in Catalonia there was a reduction in the RR for bronchiolitis hospital admissions in the youngest infants aged <6 months (0.52, 95% CI: 0.48-0.55). There was also a reduction in Catalonia in the RR for hospital attendances for bronchiolitis in nirsevimab eligible age groups (0-11 months), with a RR of 0.56 (95% CI: 0.54-0.58) for infants <6 m and 0.93 (95% CI: 0.89-0.97) for infants 6-11 m. None of the other sites or age groups showed a significant reduction in the RR for attendances or admissions for the 2023-2024 season compared to previous years.
Nirsevimab had a clear impact in reducing attendances and admissions for infants with bronchiolitis aged <6 months in Catalonia. However, the impact on older infants was less clear.
None.
尼塞韦单抗是一种新型单克隆抗体，半衰期长，已获得欧盟批准，用于预防首次接触呼吸道合胞病毒（RSV）季节期间由其引起的下呼吸道感染（LRTIs）。它于2023 - 2024赛季在西班牙加泰罗尼亚实施。我们的主要目标是通过比较西班牙加泰罗尼亚地区与英国五个地点和意大利罗马的就诊情况，分析尼塞韦单抗对加泰罗尼亚地区急诊科（ED）因LRTIs就诊的影响。
在这项关于急诊科就诊和住院情况的多国回顾性分析中，我们回顾性收集了2018年5月1日至2024年4月30日期间，西班牙加泰罗尼亚地区68家医院、意大利罗马一家医院以及英国四家医院（布里斯托尔、莱斯特、格拉斯哥和爱丁堡）不同年龄组的所有诊断、排除细支气管炎的呼吸道诊断以及细支气管炎的信息。在泊松回归中应用广义线性模型（GLM），我们获得了2023 - 2024赛季与之前所有赛季均值相比细支气管炎的风险比（RR）和95%置信区间（CI）。我们按年度区间（5月1日至4月30日）分析数据，不包括2020 - 2021年这个新冠疫情年，总共5年的数据。
有1,574,392例急诊科就诊数据（细支气管炎96,028例）和255,689例住院数据（细支气管炎27,691例）。在2023 - 2024赛季，在加泰罗尼亚，6个月以下最年幼婴儿因细支气管炎住院的RR有所降低（0.52，95%CI：0.48 - 0.55）。在加泰罗尼亚，尼塞韦单抗适用年龄组（0 - 11个月）因细支气管炎就诊的RR也有所降低，6个月以下婴儿的RR为0.56（95%CI：0.54 - 0.58），6 - 11个月婴儿的RR为0.93（95%CI：0.89 - 0.97）。与前几年相比，2023 - 2024赛季其他地点或年龄组的就诊或住院RR均未出现显著降低。
尼塞韦单抗对加泰罗尼亚地区6个月以下患细支气管炎婴儿的就诊和住院情况有明显影响。然而，对年龄较大婴儿的影响不太明确。
无。
